Systematic Review and Pooled Analysis of Functional and Sexual Outcomes of Minimally Invasive Surgical Treatments for Benign Prostatic Obstruction.

Fecha de publicación: 17/09/2025 Fecha Ahead of Print: 17/09/2025

Autores de IIS La Fe

Salvador Arlandis Guzmán

Autor

Participantes ajenos a IIS La Fe

Franco A
Ditonno F
Manfredi C
Bologna E
Licari LC
Orecchia L
Finazzi Agró E
Antonelli A
Autorino R
Tarcan T
Cornu JN
Elterman D
Kaplan S
Lombardo R
McVary K
Secco S
Cindolo L
De Nunzio C

Grupos

Urología

Abstract

BACKGROUND AND OBJECTIVE: Minimally invasive surgical treatments (MISTs) for benign prostatic obstruction have been developed with the aim of providing superior symptom relief in comparison to pharmacological treatment, while minimizing the impact on sexual function. The aim of our study was to assess key MIST outcomes and to propose a definition of procedural success. METHODS: A systematic literature search was conducted in February 2025 in the PubMed, Scopus, Web of Science, and Cochrane Library databases. The protocol, which follows the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines and PICOS (Population, Intervention, Comparator, Outcomes, Study design) criteria, was registered on PROSPERO as CRD42024543361. The review focused on randomized controlled trials and prospective studies evaluating surgical and functional outcomes of MISTs (Rezum, UroLift, temporary implantable nitinol device [iTind], transperineal laser ablation [TPLA], Optilume) for BPO. We assessed the risk of bias and graded the certainty of evidence from the articles included. Pooled analyses were performed to compare perioperative and functional outcomes between study groups. KEY FINDINGS AND LIMITATIONS: The 24 studies included in the review found that most MISTs were effective, showing improvements at 12 mo of =50% in the International Prostate Symptom Score (IPSS) and maximum flow rate (Qmax), and of =1 point for at quality of life (QoL) questionnaire. Anejaculation rates were 5% with TPLA, 3% with Rezum, 1% with iTIND, and 0% with UroLift and Optilume. Complication and retreatment rates were low, although the follow-up duration was inconsistently reported and mainly limited to 24 mo. On the basis of these results, we propose a definition of procedural success that comprises achievement of all the following outcomes: IPSS reduction of =50%, Qmax improvement of =50%, QoL improvement of =50% (or =1 point), the absence of intraoperative complications and Clavien-Dindo grade =III postoperative complications, and preservation of erectile function and of antegrade ejaculation. CONCLUSIONS AND CLINICAL IMPLICATIONS: MISTs represent a promising tool for benign prostatic obstruction management and provide effective symptom relief while preserving sexual function.

Datos de la publicación

ISSN/ISSNe:: 0302-2838, 1873-7560
Tipo:: Article
Páginas:: 318-331
DOI:: 10.1016/j.eururo.2025.09.004
PubMed:: 40967932
Enlace a otro recurso:: www.scopus.com
Factor de Impacto:: 6,184 SCImago ℠
Cuartil:: Q1 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

Keywords

Benign prostatic hyperplasia; Ejaculation sparing; Minimally invasive techniques; Prostate enlargement

Cita

Cita Bibliográfica